Navalign LLC cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 10.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,739 shares of the medical research company’s stock after selling 212 shares during the period. Navalign LLC’s holdings in Thermo Fisher Scientific were worth $923,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Halpern Financial Inc. boosted its position in shares of Thermo Fisher Scientific by 307.7% in the third quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 40 shares during the period. Coppell Advisory Solutions LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at about $33,000. Live Oak Investment Partners bought a new position in Thermo Fisher Scientific in the 4th quarter valued at about $36,000. Tyler Stone Wealth Management acquired a new position in Thermo Fisher Scientific during the second quarter valued at approximately $37,000. Finally, Indiana Trust & Investment Management CO bought a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at $38,000. Institutional investors and hedge funds own 89.23% of the company’s stock.
Insider Activity at Thermo Fisher Scientific
In related news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 in the last three months. 0.32% of the stock is owned by insiders.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on TMO
Thermo Fisher Scientific Stock Performance
Shares of NYSE TMO traded up $1.84 during mid-day trading on Thursday, hitting $581.21. The company had a trading volume of 1,034,640 shares, compared to its average volume of 1,617,943. The stock’s 50-day moving average price is $565.13 and its 200-day moving average price is $520.22. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The company has a market capitalization of $221.62 billion, a price-to-earnings ratio of 37.63, a P/E/G ratio of 2.39 and a beta of 0.80.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company had revenue of $10.89 billion for the quarter, compared to analysts’ expectations of $10.73 billion. During the same period in the prior year, the business earned $5.40 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was down 4.9% compared to the same quarter last year. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.
Thermo Fisher Scientific Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be issued a dividend of $0.39 per share. The ex-dividend date is Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.10%.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
- Five stocks we like better than Thermo Fisher Scientific
- Basic Materials Stocks Investing
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Dividend Capture Strategy: What You Need to Know
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Are Penny Stocks a Good Fit for Your Portfolio?
- Disney Stock Catches 3 Upgrades In a Single Week
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.